Fundraising Fox
/Companies
Sign in

CaroGen Corporation

Farmington, US · Founded 2012 · 10 employees on LinkedIn · 1 known investors

Find your way into CaroGen Corporation

Sign up to see every warm intro you have to CaroGen Corporation

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the CaroGen Corporation team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

CaroGen Corporation develops immunotherapies for cancer and infectious diseases based on an enveloped self-amplifying mRNA (virus-like vesicle) platform, with lead candidates including CARG-2020 for ovarian and other cancers and CARG-201 for hepatitis B. The company works with academic and government partners such as Wayne State University, UConn Health, and NIH/NIAID.

BiotechHealthtech

Founders & leadership

CaroGen Corporation was founded in 2012 by Bijan Almassian.

BABijan Almassian
Bijan AlmassianCEOBijan Almassian is the co-founder and CEO of CaroGen Corporation, a biotechnology company spun out of Yale School of Medicine that develops virus-like vesicle (VLV) immunotherapies for cancer and chronic infections. He has decades of experience in life science company formation, venture strategy, licensing, intellectual property development, and translational medicine, and currently focuses on advancing immunotherapies such as CARG-2020 aimed at preventing cancer recurrence.
VNValerian Nakaar
Valerian NakaarChief Scientific Officer & Board MemberChief Scientific Officer and board member of CaroGen Corporation, which develops immunotherapies for cancer and infectious diseases using an enveloped self-amplifying mRNA platform.
DC
Deborah ChurchChief Medical Officer
KL
King LeeVP, Regulatory Affairs
TY
Timur YarovinksyVP, Discovery
JR
Joseph RiningerVP, Product Development

Investors · 1

Founder mafia

2 people who came through CaroGen Corporation went on to found or lead other companies.

Bijan AlmassianCEOFounded Carogen CorporatonValerian NakaarChief Scientific Officer & Board MemberFounded Carogen Corporaton

Related companies · 5

Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
CompugenCompugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.
WugenAllotera (formerly Wugen) develops allogeneic T-cell therapies. The company focuses on cell and gene therapy approaches for treating disease.
CullgenCullgen is a privately held biopharmaceutical company developing first-in-class drugs based on its uSMITE™ (small-molecule induced ubiquitin-dependent target elimination) targeted protein degradation platform, which uses the ubiquitin-proteasome system and E3 ubiquitin ligases to target disease-causing proteins that conventional small-molecule drugs cannot reach. The company focuses on oncology and immune-related diseases and operates R&D and offices in both China and the United States.
PrecigenPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.

Companies working in the same space as CaroGen Corporation.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$3M
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$300K
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$1.4M
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$224.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does CaroGen Corporation do?
CaroGen Corporation develops immunotherapies for cancer and infectious diseases based on an enveloped self-amplifying mRNA (virus-like vesicle) platform, with lead candidates including CARG-2020 for ovarian and other cancers and CARG-201 for hepatitis B. The company works with academic and government partners such as Wayne State University, UConn Health, and NIH/NIAID.
Who founded CaroGen Corporation?
CaroGen Corporation was founded by Bijan Almassian in 2012.
Who are CaroGen Corporation's investors?
CaroGen Corporation's investors include Connecticut Innovations.
Where is CaroGen Corporation headquartered?
CaroGen Corporation is headquartered in Farmington, US.